

## References

### I-165

1. Wilcox MH, Gering DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. *N Engl J Med.* 2017;305-17.
2. Merck Sharp & Dohme Corp. A study of MK-6072 and MK-3415A in participants receiving antibiotic therapy for clostridium difficile infection (MK-3415A-002) (MODIFY 11). NLM Identifier: NCT01513239.
3. Merck Sharp & Dohme Corp. A study of MK-3415, MK-6072, and MK-3415A in participants receiving antibiotic therapy for clostridium difficile infection (MK-3415A-001) (MODIFY I). NLM Identifier: NCT01241552.
4. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Bezlotoxumab. Accessed March 22, 2017.
5. Thomson Micromedex DrugDex Compendium®. Bezlotoxumab [Contained in: zinplava] 2017.
6. Zinplava™ (bezlotoxumab) for injection [package insert]. Merck Sharp & Dohme Corp. Whitehouse Station, NJ. [Revised 10/2016](#).
7. Medical Letter on Drugs and Therapeutics. Bezlotoxumab (Zinplava) for prevention of recurrent Clostridium Difficile infection. *JAMA.* 2017;318(7):659-660.
8. Prabhu VS, Comely OA, Golan Y, et al. Thirty-day readmissions in hospitalized patients who received bezlotoxumab with antibacterial treatment for Clostridium difficile infection. *Clin Infect Dis.* 2017;65(7): 1218–1221.
9. Zinplava (bezlotoxumab), injection, for intravenous use [package insert]. Merck and Co. Whitehouse Station, NJ. Revised 10/2016.
10. Hengel RL, Ritter TE, Nathan RV, et al. Real-world experience of bezlotoxumab for prevention of clostridioides difficile Infection: A retrospective multicenter cohort study. *Open forum infectious diseases.* 2020;7(4):ofaa097.
11. Golan Y, DuPont HL, Aldomiro F, et. al. Renal impairment, c. difficile recurrence, and the differential effect of bezlotoxumab: A post hoc analysis of pooled data from 2 randomized clinical trials. *Open forum infectious diseases.* 2020;7(7):ofaa248.
12. Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, et al. Real-world experience with bezlotoxumab for prevention of recurrence of clostridioides difficile infection. *Journal of clinical medicine.* 2020;10(1).
13. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Bezlotoxumab.